Posted by Michael Wonder on 07 Feb 2018
PHARMAC widening access to Truvada for the prevention of HIV infection
7 February 2018 - Decision means Truvada will be funded for pre-exposure prophylaxis in New Zealand before Australia.
A decision to widen access to Truvada to prevent infection with HIV is a great opportunity to reduce transmission rates of HIV infections in New Zealand, says PHARMAC Chief Executive Sarah Fitt.
From 1 March 2018 emtricitabine with tenofovir disoproxil fumarate (Truvada) will be funded for the prevention of HIV infection (a treatment known as pre-exposure prophylaxis, or PrEP). Truvada is already funded for treating people infected with HIV, however this decision means it will also be funded for people if they are not infected but are at a high risk of contracting HIV.
